Dry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome), By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), By Type (Prescription v/s Over The Counter), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, and Competition

Industry : Healthcare
Pages : NA
Published Date : NA

Customization Enquiry

Buy Now

Single User Licence

$4500

Multi-User Licence

$5500

Custom Research Licence

$8000

Summary

Request Sample

Report Description

The Global Dry Eye Syndrome Treatment Market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing prevalence of dry eye syndrome due to certain diseases such as rheumatoid arthritis, thyroid diseases, and lupus across the globe. Besides, increasing drug approvals and launches of new eye drops along with rising research and development activities in the healthcare sector for the development of new treatments for dry eye diseases across the globe are further expected to support the dry eye syndrome treatment market during the forecast period. In the U.S., more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Also, the growing development of intranasal tear neurostimulation devices which will increase in tear production in adults along with the development of new treatment modalities will boost the market growth during the forecasted period. Also, the rising number of new players in the market is anticipated to lead the regulatory approvals and further propel the growth of the market. One of the primary challenges facing the dry eye syndrome treatment market is a lack of awareness among the general public about the condition and available treatment options. Many people may not realize that their dry, itchy, or irritated eyes are the result of dry eye syndrome or may not be aware of the range of treatment options available to them. This lack of awareness can result in delayed diagnosis and treatment, leading to prolonged discomfort and potential complications. Another significant challenge facing the dry eye syndrome treatment market is the cost of treatment. While some treatment options, such as artificial tears, are relatively inexpensive, others, such as prescription medications and procedures like LipiFlow, can be costly. Many insurance plans may not cover the full cost of treatment, leaving patients with significant out-of-pocket expenses. Like all medications and medical procedures, dry eye syndrome treatments can have side effects. Prescription medications, in particular, may have significant side effects, such as blurred vision, eye irritation, and increased risk of infection. Patients must weigh the potential benefits of treatment against the potential risks and side effects, and in some cases, may need to try several different treatment options before finding one that works well for them. Alternative treatments, such as home remedies and herbal supplements, may compete with traditional dry eye syndrome treatments. While some of these alternative treatments may provide relief for some people, others may be ineffective or even harmful. It is important for patients to discuss any alternative treatments they are considering with their healthcare provider and to avoid treatments that are unproven or potentially harmful.

Growing Prevalence of Dry Eye Disease

Most common dry eye disease is chronic ophthalmic disorder which has high prevalence rate among aging population compared to adults. Growing usage of screens, consuming improper diet, growing usage of contact lenses and rising the number of LASIK surgeries across the globe will further drive the market growth in the forecast period. Due to increasing age, the ability of the lachrymal glands to produce tears decreases that is leading to dry eye condition which is one of the key factors contributing to demand for the dry eye syndrome and drive the growth of the market during the forecasted period. Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED. The increasing availability of over-the-counter (OTC) treatments is another driver of the Global Dry Eye Syndrome Treatment Market. OTC treatments such as artificial tears and lubricating eye drops have become more readily available, making it easier for people to manage their dry eye symptoms without the need for a prescription. This has led to an increase in self-medication, which has further boosted the demand for dry eye syndrome treatment. The growing awareness and understanding of dry eye syndrome is also contributing to the growth of the Global Dry Eye Syndrome Treatment Market. More people are becoming aware of the condition, its symptoms, and the available treatment options. This increased awareness is leading to earlier diagnosis and treatment, which is improving patient outcomes and driving the overall growth of the market. As people get older, their eyes tend to produce fewer tears. This can lead to dry eye syndrome, particularly in women after menopause. Aging also makes it harder for the body to produce the necessary nutrients and fluids to maintain eye health. Environmental factors, such as air conditioning, heating, wind, and low humidity, can cause the eyes to become dry and irritated. Exposure to air pollution, smoke, and other irritants can also contribute to dry eye syndrome. Many people spend a significant amount of time in front of screens, such as computers, smartphones, and televisions. This can cause the eyes to become strained and dry, leading to dry eye syndrome. Some medications, such as antihistamines, decongestants, and antidepressants, can cause dry eye syndrome as a side effect. Medical conditions, such as diabetes, rheumatoid arthritis, and thyroid disorders, can increase the risk of developing dry eye syndrome.

Growing investment in Healthcare Industry

Furthermore, growing initiatives by public and private organizations to spread awareness about new treatment of dry eye syndrome will propel the dry eye syndrome treatment market over the years. Changing dietary pattern and sedentary lifestyle are the factors that will influence the market dynamics during the forecast period. Increasing the number of eye care centres across the globe and growing penetration of OTC eyedrop market across the developing regions will further boost the market growth in the forecast period. In January 2022, Sun Pharma announced the launch of dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nanomicellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration. Another key driver of the Global Dry Eye Syndrome Treatment Market is the development of new and innovative treatment options. In recent years, there has been significant investment in research and development, leading to the discovery of new treatment options such as LipiFlow, a thermal pulsation system that uses heat and massage to clear blocked oil glands in the eyelids. These new treatment options have not only improved patient outcomes but have also increased the overall demand for dry eye syndrome treatment. LipiFlow is a thermal pulsation system that uses heat and massage to clear blocked oil glands in the eyelids, which can improve tear quality and reduce dry eye symptoms. The procedure is typically performed in a doctor's office and takes approximately 12 minutes per eye. LipiFlow is considered a safe and effective treatment for dry eye syndrome.

Recent Development

Cequa (cyclosporine ophthalmic solution) 0.09% was launched by Sun Pharma in 2018 as a prescription medication for the treatment of dry eye syndrome. Cequa is a calcineurin inhibitor that works by reducing inflammation and increasing tear production. It is the first and only approved ophthalmic solution with a nanomicellar technology that helps to improve drug penetration and efficacy.
Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% was launched by Kala Pharmaceuticals in 2020 as a prescription medication for the short-term treatment of the signs and symptoms of dry eye syndrome. Eysuvis is a corticosteroid that works by reducing inflammation and improving tear production. It is the first and only approved corticosteroid for the treatment of dry eye syndrome.
Klarity-C (ascorbic acid 6% and glycyrrhetinic acid 1% ophthalmic solution) was launched by ImprimisRx in 2020 as a prescription medication for the treatment of dry eye syndrome. Klarity-C is a combination of two ingredients, ascorbic acid (vitamin C) and glycyrrhetinic acid, that work together to reduce inflammation and improve tear production.
Klarity is a new over-the-counter dry eye syndrome medication that was launched in 2021. It is a preservative-free eye drop solution that contains hyaluronic acid, which is a naturally occurring substance in the body that helps to retain moisture. Klarity eye drops work by moisturizing the eyes and providing long-lasting relief from dry eye syndrome.

Download Free Sample Report

Market Segmentation

The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over the Counter. Based on distribution channel, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global dry eye syndrome treatment market on account of growing demand for dry eye treatment in the country.

Recent Development

In 2019 October, Sun Pharmaceutical Industries Ltd launched a product CEQUA for the treatment of dry eye syndrome in the U.S. and the highest concentration of cyclosporine for ophthalmic use which is approved by the U.S. FDA.
In 2019 July, Novartis announced the completion of the successful acquisition of Xiidra 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by controlling the inflammation caused by the disease.

Market Players

Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.

Attribute	Details
Base Year	2022
Historic Data	2018 – 2021
Estimated Year	2023
Forecast Period	2024 – 2028
Quantitative Units	Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
Report Coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments Covered	· By Indication · By Product Type · By Dosage Form · By Type · By Distribution Channel · By Region
Regional scope	North America; Europe; Asia Pacific; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE
Key companies profiled	Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc.
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global dry eye syndrome treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

o Evaporative Dry Eye Syndrome

o Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

o Cyclosporine

o Topical Corticosteroids

o Artificial Tears

o Punctal Plugs

o Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

o Gels

o Eye Solutions

o Capsules & Tablets

o Eye Drops

o Ointments

Dry Eye Syndrome Treatment Market, By Type:

o Prescription

o Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

North America

United States
Mexico
Canada

Europe

France
Germany
United Kingdom
Italy
Spain

Asia Pacific

China
India
Japan
South Korea
Australia

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Dry Eye Syndrome Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Dry Eye Syndrome Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials

5.2. Completed Clinical Trials

5.3. Terminated Clinical Trials

5.4. Breakdown of Pipeline, By Development Phase

5.5. Breakdown of Pipeline, By Status

5.6. Breakdown of Pipeline, By Study Type

5.7. Breakdown of Pipeline, By Region

5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome)

6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)

6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)

6.2.4. By Type (Prescription v/s Over The Counter)

6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

6.2.6. By Region

6.2.7. By Company (2022)

6.3. Market Map

6.3.1. By Indication

6.3.2. By Product Type

6.3.3. By Dosage Form

6.3.4. By Type

6.3.5. By Distribution Channel

6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Indication

7.2.2. By Product Type

7.2.3. By Dosage Form

7.2.4. By Type

7.2.5. By Distribution Channel

7.2.6. By Country

7.3. North America: Country Analysis

7.3.1. United States Dry Eye Syndrome Treatment Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Indication

7.3.1.2.2. By Product Type

7.3.1.2.3. By Dosage Form

7.3.1.2.4. By Type

7.3.1.2.5. By Distribution Channel

7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Indication

7.3.2.2.2. By Product Type

7.3.2.2.3. By Dosage Form

7.3.2.2.4. By Type

7.3.2.2.5. By Distribution Channel

7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Indication

7.3.3.2.2. By Product Type

7.3.3.2.3. By Dosage Form

7.3.3.2.4. By Type

7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Indication

8.2.2. By Product Type

8.2.3. By Dosage Form

8.2.4. By Type

8.2.5. By Distribution Channel

8.2.6. By Country

8.3. Europe: Country Analysis

8.3.1. France Dry Eye Syndrome Treatment Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Indication

8.3.1.2.2. By Product Type

8.3.1.2.3. By Dosage Form

8.3.1.2.4. By Type

8.3.1.2.5. By Distribution Channel

8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Indication

8.3.2.2.2. By Product Type

8.3.2.2.3. By Dosage Form

8.3.2.2.4. By Type

8.3.2.2.5. By Distribution Channel

8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Indication

8.3.3.2.2. By Product Type

8.3.3.2.3. By Dosage Form

8.3.3.2.4. By Type

8.3.3.2.5. By Distribution Channel

8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Indication

8.3.4.2.2. By Product Type

8.3.4.2.3. By Dosage Form

8.3.4.2.4. By Type

8.3.4.2.5. By Distribution Channel

8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Indication

8.3.5.2.2. By Product Type

8.3.5.2.3. By Dosage Form

8.3.5.2.4. By Type

8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Indication

9.2.2. By Product Type

9.2.3. By Dosage Form

9.2.4. By Type

9.2.5. By Distribution Channel

9.2.6. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China Dry Eye Syndrome Treatment Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Indication

9.3.1.2.2. By Product Type

9.3.1.2.3. By Dosage Form

9.3.1.2.4. By Type

9.3.1.2.5. By Distribution Channel

9.3.2. India Dry Eye Syndrome Treatment Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Indication

9.3.2.2.2. By Product Type

9.3.2.2.3. By Dosage Form

9.3.2.2.4. By Type

9.3.2.2.5. By Distribution Channel

9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Indication

9.3.3.2.2. By Product Type

9.3.3.2.3. By Dosage Form

9.3.3.2.4. By Type

9.3.3.2.5. By Distribution Channel

9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Indication

9.3.4.2.2. By Product Type

9.3.4.2.3. By Dosage Form

9.3.4.2.4. By Type

9.3.4.2.5. By Distribution Channel

9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Indication

9.3.5.2.2. By Product Type

9.3.5.2.3. By Dosage Form

9.3.5.2.4. By Type

9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Indication

10.2.2. By Product Type

10.2.3. By Dosage Form

10.2.4. By Type

10.2.5. By Distribution Channel

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Indication

10.3.1.2.2. By Product Type

10.3.1.2.3. By Dosage Form

10.3.1.2.4. By Type

10.3.1.2.5. By Distribution Channel

10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Indication

10.3.2.2.2. By Product Type

10.3.2.2.3. By Dosage Form

10.3.2.2.4. By Type

10.3.2.2.5. By Distribution Channel

10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Indication

10.3.3.2.2. By Product Type

10.3.3.2.3. By Dosage Form

10.3.3.2.4. By Type

10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Indication

11.2.2. By Product Type

11.2.3. By Dosage Form

11.2.4. By Type

11.2.5. By Distribution Channel

11.2.6. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Indication

11.3.1.2.2. By Product Type

11.3.1.2.3. By Dosage Form

11.3.1.2.4. By Type

11.3.1.2.5. By Distribution Channel

11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Indication

11.3.2.2.2. By Product Type

11.3.2.2.3. By Dosage Form

11.3.2.2.4. By Type

11.3.2.2.5. By Distribution Channel

11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Indication

11.3.3.2.2. By Product Type

11.3.3.2.3. By Dosage Form

11.3.3.2.4. By Type

11.3.3.2.5. By Distribution Channel

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments

13.2. Mergers & Acquisitions

13.3. Product Launches

14. Competitive Landscape

14.1. Business Overview

14.2. Product Offerings

14.3. Recent Developments

14.4. Financials (As Reported)

14.5. Key Personnel

14.6. SWOT Analysis

14.6.1. Johnson & Johnson

14.6.2. AbbVie Inc.

14.6.3. Bausch Health Companies Inc.

14.6.4. Novartis AG

14.6.5. Sun Pharmaceuticals Industries Limited

14.6.6. Santen Pharmaceutical Co., Ltd.

14.6.7. Otsuka Pharmaceutical Co., Ltd.

14.6.8. Oyster Point Pharma, Inc.

14.6.9. Alcon Inc.

14.6.10. GlaxoSmithKline plc.

Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Dry Eye Syndrome Treatment Market?

The growing prevalence of dry eye syndrome among the population and rising initiatives by public and private organizations to spread awareness about new treatments are some of the major factors driving the growth of the global dry eye syndrome treatment market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Dry Eye Syndrome Treatment Market to be dominated by Cyclosporine Type through 2028

Dec, 2022

The growing prevalence of dry eye syndrome is expected to drive the growth of the global dry eye syndrome treatment market in the forecast period,2024-2028.